PFE · NYSE · STOCK
Pfizer (PFE) Stock Analysis
$27.48
52W $23.58 – $29.21
53/100
$157.02B
36.4
0.30
Is PFE Bullish or Bearish?
Mixed.
Innellis AI committee rates Pfizer Inc. (PFE) Watch with a composite score of 53/100
, based on 5 analysts with 40% agreement.
Last updated September 17, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +6.98 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -13.02 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Growth Analyst remains cautious — revenue declining -0.2% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Dividend yield of 5.4% pays you to wait — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 36.2 is moderate-to-rich — Value
- ROE of only 4.9% -- cheap may mean cheap for a reason — Value
- Revenue declining -0.2% YoY -- this is not a growth story right now — Growth
- EPS declining -59.9% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 17, 2026
Overall Committee Score
53/100
Agreement
40%
Analysts
5
Conviction
Contested
Sector Rank
Top 79%
of 192 Healthcare peers
Value Analyst
neutral
42
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ Dividend yield of 5.4% pays you to wait
− P/E of 36.2 is moderate-to-rich
Growth Analyst
bearish
38
/ 100 · High confidence
Growth story is weak, decelerating, or inconsistent
+ 5 consecutive earnings beats -- consistent execution
− Revenue declining -0.2% YoY -- this is not a growth story right now
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2514.55)
Investment Thesis Evolution
Committee score moved marginally from 53.0 to 53.0.
Comparing 2026-09-16 to 2026-09-17 (1 day apart).
Technical Analysis
RSI (14)
38.8
Neutral
MACD Histogram
-0.200
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$25.19
Resistance
$27.57
Bollinger %B
0.20
Inside Bands
Price vs Moving Averages
EMA 9
$27.87
Below
EMA 21
$27.71
Below
EMA 50
$26.94
Above
EMA 200
$26.16
Above
Fundamental Analysis
Valuation
70
Growth
68
Profitability
54
Financial Health
63
Cash Flow
70
Valuation
P/E Ratio
36.4×
P/B Ratio
1.84×
PEG Ratio
-0.61
Dividend Yield
6.24%
52W High
$29.21
52W Low
$23.58
Quality & Growth
ROE
898.5%
ROA
373.3%
Gross Margin
7132.2%
Operating Margin
2508.2%
Revenue Growth YoY
—
Debt / Equity
0.74
AI Fundamental Assessment
P/E ratio of 36.4 (rich relative to a 15-40x range); Price-to-book of 1.8x; PEG ratio of -0.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 9.0%; Return on assets of 3.7%; Net margin of 6.8%; Gross margin of 71.3%; Current ratio of 1.27 (tight short-term liquidity); Debt-to-equity of 0.74; Free cash flow per share is positive (1.93); Most recent quarter beat estimates by 11.4%; 5 consecutive earnings beats; EPS growth decelerating (+13.6% -> +2.7% QoQ); Average YoY EPS growth of -1.3%; Analyst estimates rising over recent quarters
Get the Full PFE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →